Heparin in clinical doses 'primes' granulocytes to subsequent activation as measured by myeloperoxidase release.
The author pre-incubated isolated human granulocytes with increasing doses of heparin (0-100 IU/mL) before subsequent stimulation with formyl-met-leu-phe. There was a dose-dependent increase in granulocyte activation as measured by myeloperoxidase release, quantitated in enzyme-immunoassay. This 'priming' effect of heparin was not due to activation of contaminating platelets or to endotoxin, and there was no reduction in granulocyte viability. Heparin-induced 'priming' of granulocytes may be clinically relevant in the setting of cardiopulmonary bypass. The author describes a sensitive and specific double antibody enzyme-immunoassay for myeloperoxidase from human granulocytes, with an inter-assay coefficient of variation of 12.6%, an intra-assay coefficient of variation of 4.3%, and a lower detection limit of 1.8 microg/l.
Videm
V
V
Surgical Department A, Institute for Surgical Research, The National Hospital, Oslo, Norway.
D002315:Cardiopulmonary Bypass; D004305:Dose-Response Relationship, Drug; D006098:Granulocytes / Q000737:chemistry / Q000187:drug effects* / Q000201:enzymology*; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007124:Immunoenzyme Techniques; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D018375:Neutrophil Activation / Q000187:drug effects; D009195:Peroxidase / Q000737:chemistry / Q000378:metabolism*
D009240:N-Formylmethionine Leucyl-Phenylalanine; D006493:Heparin; D009195:Peroxidase